Navigation Links
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
Date:7/14/2008

MOUNTAIN VIEW, Calif., July 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine.

MAP0004 is orally inhaled and self-administered at home using MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In the company's prior Phase 2 efficacy study, MAP0004 provided pain relief in as fast as 10 minutes, with relief sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia, the other key measurements in treating migraine.

This randomized, double-blind, placebo-controlled Phase 3 trial is designed to evaluate the efficacy and safety of MAP0004 in treating acute migraine. The primary efficacy endpoints will be pain relief, and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. MAP will also evaluate earliest onset of pain relief and sustained relief to 24 and 48 hours. The multi-center efficacy trial will include approximately 850 patients, who will also be followed for 12 months in an open-label study to confirm long-term safety.

"We believe that MAP0004 has the potential to be a first-line therapy for migraine patients," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Based on our initial clinical studies, we believe that MAP0004 offers an alternative to triptans that may provide patients with the benefits of rapid onset and long-lasting pain relief, in an easy-to-use, non-invasive, at-home therapy. In our Phase 2 trials, MAP0004 was well tolerated with no effect on pulmonary function, including in asthmatic subjects."

The therapeutic agent
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... DIEGO , Sept. 19, 2014  Lpath, ... leader in bioactive lipid-targeted therapeutics, announced today that ... 3,605,042 registered shares of common stock and 3,605,042 ... combined purchase price for one registered share of ... one unregistered share of common stock will be ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. 19, ... therapy continues to grow, with the publication of two ... in Otolaryngology – Head and Neck Surgery ... worsening of both objective and subjective measures of sleep ... Inspire therapy for the reduction in obstructive sleep apnea ...
(Date:9/19/2014)... 2014  Over 200 runners participated in the fifth ... Radiation Oncology Institute (ROI), hosted by Radiation Business Solutions. This ... in San Francisco.  "Donations are still ... Radiation Business Solutions, "but at this point, through ... for the ROI this year. This surpasses last year,s ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... Rochester Medical Corporation (Nasdaq: ROCM ) today announced that it is ... healthcare alliance. , , , ... with more than 800 suppliers and Rochester Medical is one of 38 ... outstanding management of Premier agreements and drive toward the mutual goal of ...
... June 22 Hospira, Inc. (NYSE: HSP ... it has received U.S. Food and Drug Administration (FDA) approval ... g vials.  The medication, a carbapenem that belongs to the ... Merrem® I.V. Sales of the name-brand product in ...
Cached Medicine Technology:Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 2Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 3Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.) 2Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.) 3
(Date:9/20/2014)... SATURDAY, Sept. 20, 2014 (HealthDay News) -- As flu ... avoid infection is to get a flu shot and ... A primary care doctor can vaccinate people against ... issues patients may have. Retail stores may provide flu ... medical advice, said Dr. Jorge Parada, medical director of ...
(Date:9/20/2014)... New PharmaPoint Drug Evaluation report, ... 2023?. The asthma market saw very slow growth ... saturated with relatively efficacious standard therapies, such as ... and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and ... the launch of seven novel targeted biologic agents ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
(Date:9/20/2014)... 20, 2014 "As a nurse, patients always ... said an inventor from Tamaqua, Pa. "The reason that they ... backs of their chairs. My invention enables them to check ... Oxygen Sensor to make it easier to monitor the contents ... knows when the tank is low. It allows changeovers to ...
(Date:9/20/2014)... New York, NY (PRWEB) September 20, 2014 ... million of their customers may have had their credit card ... late last year, spawning a slew of headline articles ... but those weren’t the only eye opening numbers. , ... numbers were stolen, almost like it’s a way to score ...
Breaking Medicine News(10 mins):Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5
... in Maryland, USA, has launched a major initiative against the ... all mothers who deliver their babies at the Centre to ... ,Shaking a baby too hard could result in ... ,Nearly 70 percent of shaken baby syndrome cases ...
... prevent bites and therefore don’t prevent disease transmission, according ... be manufactured, advertised or used for mosquito bite and ... lead author A. Ali Enayati, Ph.D., lecturer in medical ... Sari, Iran. ,The review appears in the ...
... surgical robot developed by the University of Washington, leaves for ... in NASA's mission to submerge a surgeon and robotic gear ... system will be put through its paces in an underwater ... in Seattle will guide its movements. ,The 12th ...
... The World Health Organization (WHO) Thursday expressed alarm over ... motorcycles in Asia//, warning that the situation has become ... that young motorcyclists make up a significant percentage of ... countries, such as Cambodia and Malaysia. ,"Factors ...
... benefits of a key ingredient in Cannabis, which may help ... that cannabis could help fight brain, prostate and skin cancers. ... growth by 50%, during studies conducted on mice, suggesting that ... the study, the researchers observed that THC was able to ...
... health workers should focus their efforts on strengthening HIV/AIDS ... not overcome the pandemic, Kevin De Cock, director of ... deputy director of UNAIDS, said on Tuesday during a ... comments follow the release of a report on Tuesday ...
Cached Medicine News:Health News:Counseling to Mothers Against too Much Shaking of Children 2Health News:Electronic Mosquito Repellents Fail to Prevent Malaria Transmission 2Health News:Robotic Surgeon to Team Up With Doctors, Astronauts on NASA Mission 2Health News:Robotic Surgeon to Team Up With Doctors, Astronauts on NASA Mission 3Health News:U.N. Officials Call on Countries To Strengthen HIV/AIDS Prevention Efforts 2
Thru cut kerrison style punch 30 deg, 2.75 X 1.4 mm cut, 110 working length....
6 mm, 45 degree upwards, detachable....
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
Sabre 180 is a powerful niche generator....
Medicine Products: